Biomerics has bought FutureMatrix Interventional, which specialises in the design and manufacture of interventional catheters for the cardiovascular and urinary markets. A press release reports that, over the years, the company expanded its percutaneous transluminal angioplasty balloon technologies and developed other peripheral cardiovascular, kidney stone management, and urinary catheters. Today, the US FDA registered location includes over 50,000 sq. ft. of manufacturing space and employs more than 400 employees.
Biomerics, with over 1,000 employees, operates seven facilities located in Utah, Minnesota, Indiana, Costa Rica, and Texas. Founded in 2009, Biomerics has grown into a market leader in the minimally invasive interventional catheter market. It provides engineered components to the medical device market including biomaterials, extrusions, moulded parts, laser processed parts, machined parts, balloons, and reinforced shafts. Additionally, it supplies packaged sterile medical devices including advanced interventional catheters, surgical tools, and vascular access products.
Travis Sessions, CEO of Biomerics, says: “We are pleased to add FutureMatrix Interventional’s capabilities to the Biomerics portfolio. We welcome the FutureMatrix Interventional team to the group, and look forward to their contribution. This acquisition expands our capabilities and important customer relationships. We look forward to investing in and expanding the business for our customers, employees, and community. Combining FutureMatrix Interventional with Biomerics’ existing medical device business establishes Biomerics as a leader in the attractive minimally invasive interventional segment of the medical device market.”